Go to content Go to menu Go to search

Accinov: the first stone is laid for the innovation platform at Lyon Gerland

26 July 2012

  • version française

On Thursday, July 5, 2012, Marc Challéat, General Secretary for Regional Affairs (S.G.A.R.) of the Rhône-Alpes prefecture, Jack Queyranne, former minister, and Gérard Collomb, President of  Greater Lyon, laid the first stone of the Accinov innovation platform. They were accompanied by Jean-Luc da Passano, President of the SERL Group, Claude Blanchet, Regional Director of the CDC, Alain Mérieux, President of the Mérieux Institute, Tristan Rousselle, President of Accinov, Philippe Archinard, President of Lyonbiopôle, and Alexis Perret, Chief Operating Officer of Nexity business real estate.

A project to help structure Lyonbiopôle

Accinov, an innovation platform which is unique in Europe, proposes an offer of services with high added value, including bioproduction units and turnkey labs, to biotechnology companies developing breakthrough technologies and innovative therapeutic products.

This project marks the second step in the development of the Lyonbiopôle infrastructure policy, which is designed to cover the entire chain of infectology innovation. Accinov continues the momentum created by the Lyonbiopôle Infectology Center, which opened in April 2009.

"Today, most therapeutic or technological innovations in the life sciences are developed within biotechnological companies. Bioproduction has thus taken on economic and strategic importance for our members. After opening the Infectology Center, providing access to a bioproduction platform to smaller companies seems to us a fundamental step toward generating long-term activity that will create values and jobs in the Rhône-Alpes region," states Philippe Archinard, President of Lyonbiopôle.

Accinov thus becomes the leading bioproduction platform designed to serve smaller biotechnological companies in Lyon Gerland. The results of research and development will enable enhancing the competitiveness of small, medium size and large companies throughout the territory.

This is an additional step in the development of Lyonbiopôle prior to the implantation of the BioAster institute of technological research, in which the State has decided to invest €180,000,000.

Accinov, future center of open innovation in bioproduction

Accinov is a five-storey building with turnkey facilities offering 6,500 m2 of laboratories and offices, including:

  • 3 bioproduction units and 3 quality control laboratories,
  • 18 laboratories classified as ISO8,
  • 1 area of shared support labs (washroom, sterilization, storage, cold room,
  • office areas.

Accinov will make an application to ANSM (which controls health product safety) to obtain the status of pharmaceutical establishment for the manufacture of experimental  medicines. This will enable it to offer bioproduction rooms with GPP conformity and to certify and release batches of active pharmaceutical ingredients and medicines produced by the companies housed there.

Find out more

BioAster is the only institute of technological research in health in France. It was chosen by the State in 2011 as part of the Future Investments Program.